Clinical Trial

Combination of NMDA-enhancing and Anti-inflammatory Treatments for Schizophrenia

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Previous studies found that some NMDA-enhancing agents were able to improve clinical symptoms of patients with chronic schizophrenia. In addition, several drugs with anti-inflammatory properties have been tested in clinical trials for the treatment of schizophrenia too. Whether combined treatment of an NMDA-enhancing agent and a drug with anti-inflammatory property can be better than an NMDA-enhancing agent alone deserves study.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2021-06-02; most recent amendment 2025-02-16.
Trial Details
NCT Number NCT04917302
Lead Sponsor China Medical University Hospital
Collaborators: Ministry of Science and Technology, Taiwan
Conditions Schizophrenia
Enrollment 60 participants
Start Date 2020-10-13
Primary Completion 2026-11 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-02-19